Updated:
August Global Partners
A global fund management company with an Asian orientation — investing across healthcare innovation and advanced manufacturing.
August Global Partners
A global fund management company with an Asian orientation — investing across healthcare innovation and advanced manufacturing.
General information
Firm type
Private Equity
Year founded
2023
AUM
$350M (per firm website)
Location
Region
Asia
Country
Singapore
City
Singapore
Corporate office
Parkview Square, 600 North Bridge Road, #10-01, Singapore 188778
Principals
Chu Swee Yeok
Founding Partner
Basil Lui
CEO & Founding Partner
Davian Sim
Partner
Sector focus
Frequently asked questions
Who runs investment decisions at August Global Partners?
Founding Partner Chu Swee Yeok and CEO & Founding Partner Basil Lui lead the firm. Chu previously served as CEO of EDBI and founding CEO of Bio*One Capital; Basil Lui led deep-tech, healthcare, and fund investments under her at EDBI. In 2023, Davian Sim — who also joined from EDBI — was made Partner, strengthening the leadership bench for growth equity and advanced manufacturing.
How is AGP structured — is it a single family office or an independent fund manager?
AGP is an independent, commercially oriented fund management company. It launched in 2023 with two investment vehicles — the AGP Continuation Growth Fund and the AGP Healthcare Fund — and serves a global base of financial investors, conglomerates, and institutions. The firm is not a family office.
Does AGP participate in fund commitments or only direct deals?
AGP invests through two dedicated pooled vehicles that make direct growth-stage investments. The website does not describe a fund-of-funds program; the firm's track record is built on direct equity positions in companies such as Ambiq, UltraGreen.ai, and Gene Solutions.
What investment stages does AGP typically target?
AGP targets growth-stage companies. Its Continuation Growth Fund focuses on growth equity in Southeast Asia-based healthcare services and advanced manufacturing. The Healthcare Fund backs growth-stage companies developing precision medicine, AI-powered health technologies, and patient-centric care solutions.
How is AGP connected to the Singapore government and EDBI?
Founding Partner Chu Swee Yeok previously led EDBI and Bio*One Capital, both state-backed investment platforms that built Singapore's biomedical ecosystem. AGP itself is an independent commercial entity, though it launched with support from the Singapore government and maintains deep relationships across government-linked research institutions and industry bodies.
What is AGP's posture on co-investments alongside external GPs?
AGP co-invests alongside strategic and institutional partners. In a US$188 million round for UltraGreen.ai, it invested alongside Temasek-linked 65 Equity Partners and Vitruvian Partners. The firm describes its approach as providing value-added capital and strategic support, often collaborating with specialist co-investors.
Which sectors does AGP explicitly avoid?
There is no public exclusion list. The firm's stated focus is healthcare innovation and advanced manufacturing. It does not describe mandates in consumer internet, general enterprise SaaS, commodities, or real estate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: